A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
We demonstrate how to perform macrophage MR imaging using ultrasmall superparamagnetic contrast agent (USPIO) in septic arthritis, allowing an initial and longitudinal in vivo non-invasive evaluation of macrophages infiltration and an assessment of therapy efficacy.
Macrophages are key-cells in the initiation, the development and the regulation of the inflammatory response to bacterial infection. Macrophages are intensively and increasingly recruited in septic joints from the early phases of infection and the infiltration is supposed to regress once efficient removal of the pathogens is obtained. The ability to identify in vivo macrophage activity in an infected joint can therefore provide two main applications: early detection of acute synovitis and monitoring of therapy.
In vivo noninvasive detection of macrophages can be performed with magnetic resonance imaging using iron nanoparticles such as ultrasmall superparamagnetic iron oxide (USPIO). After intravascular or intraarticular administration, USPIO are specifically phagocytized by activated macrophages, and, due to their magnetic properties, induce signal changes in tissues presenting macrophage infiltration. A quantitative evaluation of the infiltrate is feasible, as the area with signal loss (number of dark pixels) observed on gradient echo MR images after particles injection is correlated with the amount of iron within the tissue and therefore reflects the number of USPIO-loaded cells.
We present here a protocol to perform macrophage imaging using USPIO-enhanced MR imaging in an animal model of septic arthritis, allowing an initial and longitudinal in vivo noninvasive evaluation of macrophages infiltration and an assessment of therapy action.
Magnetic resonance imaging (MRI) is considered to be the imaging modality of choice for the demonstration of infectious synovitis due to its high spatial resolution and soft tissue contrast. Signal changes observed on MRI in arthritis low T1 and high T2 signal reflecting the increased presence of extracellular water content, and a marked enhancement after gadolinium based-contrast agent administration, consistent with the histologically findings of increased vascularity owing to vasodilation and angiogenesis1. Nevertheless, MRI is often unable to demonstrate resolution of infection during antibiotic therapy as persistent enhancement can be observed in the joints of patients with clinically and biologically healed septic arthritis due to persistence of enlarged extracellular space (granulation tissue, fibrotic scar)2. Besides extracellular changes, inflammatory cells including an intense recruitment of macrophages massively infiltrate the infected synovia. Macrophages play a major role in both the acute and chronic phase of bacterial infection 3. They induce the inflammatory reaction required to eradicate pathogenic microorganisms, and coordinate inflammation resolution, as macrophage-induced inflammation persists as long as necrotic tissues are not removed, preventing repair to begin4. Thus, the reduction of macrophage infiltration within infected synovia after efficient therapy can be a reliable indicator of the resolution of the infection. Cellular imaging is able to demonstrate specific cellular infiltration inside pathologic tissue. Specific macrophage MR imaging using targeted contrast agent has been widely investigated and has demonstrated its ability to demonstrate joint inflammation or infection5-7. After intravenous injection, such targeted contrast agents such as USPIO (ultrasmall superparamagnetic iron oxides) particles are taken up by phagocytic cells such as macrophages and, due to their magnetic properties, induce signal changes in tissues presenting macrophage infiltration8. The longitudinal follow up of those MR signal changes therapy allows for an in vivo noninvasive evaluation of macrophage infiltration, and a reduction of USPIO loaded-macrophages related signal changes would demonstrate therapy success. The purpose of this report is to present how to perform macrophage MR imaging to noninvasively monitor septic arthritis by demonstrating the reduction of macrophage infiltration within the synovia.
Access restricted. Please log in or start a trial to view this content.
All procedures involving animal subjects have been approved by the University Hospital Institutional Animal Care committee.
1. Intraarticular Bacterial Inoculation
2. MRI Examination
When imaging live animals, a careful animal installation is a key feature to ensure animal comfort and optimal anesthesia. This will allow for best imaging results and ensure a reproductive image acquisition for longitudinal studies. Due to the size of the animal, the use of a clinical-sized MR unit (1.5 T or 3 T) is most suitable. 8-channel clinical knee coil is used as it provides suitable resolution and contrast-to-noise ratio for rabbit knee exploration.
3. Image Analysis
Access restricted. Please log in or start a trial to view this content.
On unenhanced images, the synovium of infected knees presents a diffuse swelling of intermediate signal that is non distinguishable from surrounding soft tissue, while femur and patella appear as low signal structures (Figure 1).
On the USPIO-enhanced images, 24 hr after the contrast agent administration, synovial area containing USPIO-loaded macrophages will demonstrate signal loss (Figures 1 and 2).
Macrophage inf...
Access restricted. Please log in or start a trial to view this content.
While nonspecific gadolinium-based contrast agents provide information about the volume and perfusion of the extracellular space, macrophage imaging by USPIO-enhanced MR allows a precise anatomical localization and a qualitative evaluation of macrophage infiltration within infected synovium without the need of tissue sampling9. Due to their high sensitivity, USPIO can demonstrate even subtle cellular infiltrate present in the early phases of infection. Under successful antibiotic therapy, as the pathogens are ...
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
We sincerely thank F. Bierry for assistance in video production and editing.
Access restricted. Please log in or start a trial to view this content.
Name | Company | Catalog Number | Comments |
Name of Reagent/Material | Company | Catalog Number | Comments |
P904 | Guerbet | Dose: 150 μmol Fe/kg | |
Ketamine (500 mg/ml ketamine) | Virbac | Dose: 30 mg/kg | |
Rompun (20 mg/ml Xylazine) | Axience | Dose: 4 mg/kg | |
Buprenorphine | Vetoquinol | Dose: 0.1 mg/kg/8 hr | |
BD 22 G, 1 inch | BD Biosciences | 381423 | |
BD 25 G, 5/8 inch | BD Biosciences | 305122 |
Access restricted. Please log in or start a trial to view this content.
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved